19,000 Shares in West Pharmaceutical Services, Inc. $WST Purchased by Alberta Investment Management Corp

Alberta Investment Management Corp bought a new stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) in the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 19,000 shares of the medical instruments supplier’s stock, valued at approximately $4,157,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Zions Bancorporation National Association UT acquired a new position in shares of West Pharmaceutical Services during the first quarter worth approximately $25,000. Quarry LP bought a new stake in West Pharmaceutical Services during the 1st quarter valued at $27,000. CVA Family Office LLC boosted its position in West Pharmaceutical Services by 573.3% during the 2nd quarter. CVA Family Office LLC now owns 202 shares of the medical instruments supplier’s stock worth $44,000 after acquiring an additional 172 shares during the period. Cromwell Holdings LLC grew its stake in shares of West Pharmaceutical Services by 587.5% in the second quarter. Cromwell Holdings LLC now owns 220 shares of the medical instruments supplier’s stock worth $48,000 after purchasing an additional 188 shares in the last quarter. Finally, Brooklyn Investment Group increased its holdings in shares of West Pharmaceutical Services by 83.3% during the first quarter. Brooklyn Investment Group now owns 275 shares of the medical instruments supplier’s stock valued at $61,000 after purchasing an additional 125 shares during the period. Institutional investors own 93.90% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on WST. Rothschild & Co Redburn started coverage on shares of West Pharmaceutical Services in a report on Monday, September 15th. They issued a “buy” rating and a $311.00 price objective for the company. Deutsche Bank Aktiengesellschaft set a $345.00 price target on shares of West Pharmaceutical Services and gave the stock a “buy” rating in a research note on Friday, October 24th. KeyCorp increased their price objective on shares of West Pharmaceutical Services from $325.00 to $350.00 and gave the company an “overweight” rating in a report on Friday, October 24th. Rothschild Redb raised West Pharmaceutical Services to a “strong-buy” rating in a report on Monday, September 15th. Finally, Zacks Research lowered West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 23rd. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $349.20.

West Pharmaceutical Services Stock Performance

WST opened at $260.99 on Monday. The company has a quick ratio of 2.18, a current ratio of 2.87 and a debt-to-equity ratio of 0.07. The firm has a market cap of $18.78 billion, a PE ratio of 38.67, a P/E/G ratio of 4.09 and a beta of 1.08. The business has a fifty day simple moving average of $268.72 and a 200-day simple moving average of $241.98. West Pharmaceutical Services, Inc. has a fifty-two week low of $187.43 and a fifty-two week high of $348.90.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, October 23rd. The medical instruments supplier reported $1.96 earnings per share for the quarter, beating analysts’ consensus estimates of $1.67 by $0.29. The business had revenue of $804.60 million during the quarter, compared to analyst estimates of $788.42 million. West Pharmaceutical Services had a return on equity of 18.16% and a net margin of 16.29%.West Pharmaceutical Services’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same quarter last year, the company posted $1.85 EPS. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. As a group, equities analysts predict that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current fiscal year.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.